For no good reason, Trump and Bobby Jr. are killing one of the most promising lines of medical research
Laine
Bergeson
Federal investment in RNA vaccine research has supported
nearly three decades of scientific work spanning infectious diseases, cancer,
and vaccine development, but recent and proposed funding cuts threaten to stall
that progress, according to a cross-sectional study published
yesterday in JAMA Network Open.
Led by a team at Northwestern University, researchers
identified 178 active National Institutes of Health (NIH) grants related to RNA
vaccines from 1997 through 2025. Together, the grants represented $1.65 billion
in funding.
Many grants focused on viral vaccines (42%), including those
for COVID, HIV, and highly contagious tropical diseases, while substantial
investment also supported RNA technology and cancer research. Overall, the
grants produced 2,342 publications and nearly 150,000 citations, highlighting
what the authors describe as clear clinical impact.
RNA tech ‘could impact virtually every aspect of human
health’
“The grants we analyzed have resulted in strong scientific
output,” the researchers write. “The clinical impact of this work was apparent,
with 10% of publications classified as [sic] and 35% being cited in clinical
trials or practice guidelines.”
What’s more, 18 grants were awarded through the Small
Business Innovation Research and Small Business Technology Transfer program,
underscoring how RNA funding supports biotech entrepreneurship.
“Our study showed that RNA technology could impact virtually
every aspect of human health, from debilitating chronic diseases to conditions
even thought incurable,” lead author Anirudha S. Chandrabhatla, MD, said in a
UVA Health press release.
In an accompanying commentary, Alyson
Ann Kelvin, PhD, a veterinary medicine faculty member at the University of
Calgary, and Angela Rasmussen, PhD, a virologist at the Vaccine and Infectious
Disease Organization at the University of Saskatchewan, place the findings in
the context of mounting political and public scrutiny of RNA technology.
They note that, as antivaccine sentiment continues to rise,
approximately $500 million in RNA vaccine funding has been targeted for cuts in
2025.